Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT);Systemische therapie mit bevacizumab bei patienten mit hereditärer hämorrhagischer teleangiektasie (HHT)

Vasa - Journal of Vascular Diseases

Volumn 42, Issue 2, 2013, Pages 106-110

  Chavan, Ajay ^a   Schumann Binarsch, Silke ^a   Luthe, Lars ^a   Nickau, Britta ^a   Elsässer, Albrecht ^a   Kühnel, Thomas ^b   Geisthoff, Urban ^c   Köhne, Henning ^a  

^a KLINIKUM OLDENBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c Holweide Hospital   (Germany)

Author keywords

Arterio venous malformations; Biliary disease; Cardiac failure; Liver transplantation; Rendu Osler Weber disease

Indexed keywords

ANALGESIC AGENT; BEVACIZUMAB;

ABDOMINAL ANGINA; ADULT; ARM WEAKNESS; ARTICLE; CASE REPORT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; ECHOGRAPHY; EPISTAXIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART OUTPUT; HOARSENESS; HUMAN; HYPERTENSION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEW YORK HEART ASSOCIATION CLASS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; QUALITY OF LIFE; RENDU OSLER WEBER DISEASE; SYSTEMIC THERAPY; THROMBOEMBOLISM;

ABDOMINAL PAIN; ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARDIAC OUTPUT; DRUG ADMINISTRATION SCHEDULE; EPISTAXIS; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; OFF-LABEL USE; QUALITY OF LIFE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875155602     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000253     Document Type: Article

References (18)

1. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
2. Carmeliet P: Angiogenesis in life; disease and medicine. Nature 2005; 438: 932-936.
3. Chavan A, Caselitz M, Gratz K-F, Lotz J, Kirchhoff T, Piso P, Wagner S, Manns M, Galanski M: Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations. Eur Radiol 2004; 14: 2079-2085.
4. Dupuis-Girod S, Chesnais A-L, Ginon I, Dumortier J, Saurin J-C, Finet G, Decullier E, Marion D, Plauchu H, Boillot O: Long-Term Outcome of Patients with Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Involvement Aft er Orthotopic Liver Transplantation: a Single-Center Study. Liver Transplantation 2010; 16: 340-347.
5. Dupuis-Girod S, Ginon I, Saurin J-C, Finet G, Marion D, Decullier E, Roux A, Carette M-F, Gilbert-Dussardier B, Hatron P-Y, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette P-J, Plauchu H, Faure F: Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output. JAMA 2012; 307 (9): 948-955.
6. Flieger D, Hainke S, Fischbach W: Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006; 85: 631-632.
7. Garcia-Tsao G, Korzenik JR, Young L, Henderson KJ, Jain D, Byrd B, Pollak JS, White RI: Liver Disease in Patients with Hereditary Hemorrhagic Telangiectasia. N Engl J Med 2000; 343: 931-936.
8. Geisthoff UW, Schneider G, Fischinger J, Plinkert PK: Hereditäre hämorrhagische Teleangiectasie (Morbus Osler). HNO 2002; 50: 114-128.
9. Govani FS, Shovlin CL: Hereditary hemorrhagic telangiectasia: a clinical and scientific review. European Journal of Human Genetics 2009; 17: 860-871.
10. Guttmacher AE, Marchuk DA, White RI: Hereditary hemorrhagic telangiectasia. N Eng J Med 1995; 333 (14): 918-924.
11. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, flurouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
12. Lerut J, Orlando G, Adam R, Sabbà C, Pfitzmann R, Klempnauer J, Belghiti J, Pirenne J, Thevenot T, Hillert C, Brown CM, Gonze D, Karam V, Boillot O and the European Liver Transplant Association: Liver Transplantation for Hereditary Hemorrhagic Telangiectasia. Report of the European Liver Transplant Registry. Ann Surg 2006; 244: 854-864.
13. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Opthalmology 2005; 112: 1035-1047.
14. Mitchell A, Adams LA, Macquillan G, Tibballs J, vanden Driesen R, Delriviere L: Bevacizumab Reverses Need for Liver Transplantation in Hereditary Hemorrhagic Telangiectasia. Liver Transplantation 2008; 14: 210-213.
15. Rambusch EG, Chavan A, Harms CP, Tietge U, Ocran K, Strassburg C, Wagner S, Galanski M, Creutzig A, Manns M: Hereditäre hämorrhagische Teleangiektasie mit hepatischer Beteiligung unter Einbeziehung gastraler Gefäße. VASA 1996; 25 (4): 352-357.
16. Reilly PJ, Nostrant TT: Clinical manifestations of hereditary haemorrhagic teleangiectasia. Am J Gastroenterol 1984; 79: 363-367.
17. Sadick H, Naim R Gossler U, Hormann K, Riedel F: Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int J Mol Med 2005; 15: 15-19.
18. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24): 2542-2550.